MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Proceeds from exercise ofstock options and espp$28,006K (-24.24%↓ Y/Y)Maturities of marketablesecurities$430,000K (-15.35%↓ Y/Y)Net cash provided byfinancing activities$27,179K (-96.83%↓ Y/Y)Net cash provided byinvesting activities$24,513K (-89.24%↓ Y/Y)Canceled cashflow$827K Canceled cashflow$405,487K Net increase in cashand cash...-$37,423K (-104.25%↓ Y/Y)Canceled cashflow$51,692K Accounts payable andaccrued liabilities$68,820K (168.22%↑ Y/Y)Stock-based compensationexpense$41,254K (-4.01%↓ Y/Y)Royalty financingnon-cash interest...$5,129K (-1.21%↓ Y/Y)Depreciation$3,179K (27.98%↑ Y/Y)Amortization of intangibleassets$2,081K (64.77%↑ Y/Y)Amortization of debt issuancecosts$1,429K (-14.74%↓ Y/Y)Non-cash operating leaseexpense$819K (-7.77%↓ Y/Y)Finance leaseamortization expense$678K (0.00%↑ Y/Y)Payments of finance leaseprincipal$827K (12.98%↑ Y/Y)Purchase of marketablesecurities$399,228K (44.29%↑ Y/Y)Purchase of fixed assets$6,259K (79.65%↑ Y/Y)Net cash used inoperating activities-$88,828K (56.79%↑ Y/Y)Canceled cashflow$123,389K Effect of exchangerates on cash and cash...-$287K (-128.56%↓ Y/Y)Product revenues, net$425,486K Change in fair value ofcontingent consideration-$99,760K Investment income$10,979K Change in fair value ofcontingent consideration-$99,760K (-269.08%↓ Y/Y)Prepaid expenses andother current assets$37,643K (476.11%↑ Y/Y)Accounts receivable$37,160K (505.01%↑ Y/Y)Net loss-$13,242K (95.88%↑ Y/Y)Inventory$12,974K (160.73%↑ Y/Y)Accretion of discount onmarketable securities, net$5,464K (-27.90%↓ Y/Y)Other assets$5,230K (322.84%↑ Y/Y)Other liabilities-$744K (8.71%↑ Y/Y)Canceled cashflow$536,225K Other segment items$207,425K Sg&a compensationand...$70,520K R&d compensationand...$69,080K Cost of productrevenues (excluding...$67,212K Research anddevelopment-Other$48,836K Research anddevelopment-TPIP$38,935K Interest expense$20,273K Research anddevelopment-Brensocatib$13,829K Research anddevelopment-ARIKAYCE$6,228K Depreciation$3,179K (27.98%↑ Y/Y)Amortization of intangibleassets$2,081K (64.77%↑ Y/Y)Provision for income taxes$1,869K
Cash Flow

INSMED Inc (INSM)

INSMED Inc (INSM)

source: myfinsight.com